Uncategorized

xCures offers unparalleled access to data and the xINFORM patient portal to accelerate pancreatic cancer research and improve patient care

OAKLAND, CA – xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN).

As part of the agreement, PanCAN’s researchers and grantees will have unparalleled access to xCures’ deidentified Real-time, Regulatory-grade Clinical data. 

This collaboration aims to drive innovations and breakthroughs in pancreatic cancer research by harnessing the power of real-time patient data. xCures database boasts fully longitudinal clinical data from thousands of pancreatic cancer patients, including over 25,000 locations and ~4,000 medical records per patient.

The benefits of this partnership extend beyond the research community. xCures is making their xINFORM patient portal available to PanCAN’s leading Patient Services program.

The state-of-the-art portal aggregates and centralizes patients’ medical records and structures them into a computable format and an easy-to-understand longitudinal timeline. 

The xINFORM portal supports patients in being matched with suitable treatments and clinical programs, obtaining invaluable second opinions.

Sudheer Doss, Ph.D., Chief Business Officer of PanCAN, shared his enthusiasm for the partnership: “We’re always in search of innovative ways to serve our patient community better and accelerate pancreatic cancer research. As part of the comprehensive free services we offer through our PanCAN Patient Services program, this platform can pave the way for identifying optimal treatments and ensuring that our patients receive the best care possible.”

The PanCAN-xCures partnership blends the strengths of both organizations to advance patient outcomes and bolster research capabilities.

“We at xCures are deeply committed to placing patients at the forefront of all our endeavors,” said Mika Newton, CEO of xCures. “This new partnership with PanCan is a testament to our dedication to advancing patient-centric solutions and strengthening our bond with patient advocacy organizations. Together, we will usher in a brighter, more hopeful future for all.”

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. 

The (unstructured) data is aggregated and organized into a powerful, up-to-date care summary that helps cancer patients get the right therapy at the right time. 

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. 

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. 

For more information, contact info@xcures.com or visit http://www.xcures.com.

About PanCAN

The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official “Give with Confidence” charity, indicating strong financial health, ongoing accountability and transparency.

New study will collect, organize, and share data for Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG) research.

xCures, a leader in data-driven cancer solutions, is thrilled to announce that its platform has been highlighted as a new commitment to deliver progress on the mission of the White House Cancer Moonshot – ending cancer as we know it.

The xCures health-data technology platform has been designed to overcome a key challenge for many rare diseases: collecting, organizing, and standardizing comprehensive data from patients across the US.

In alignment with the Cancer Moonshot Initiative’s goals to reduce cancer death rates by 50% over the next 25 years, xCures is launching an ambispective natural history study of DMG and DIPG. This study will speed up the identification of patterns that can inform more personalized treatment plans and targeted therapies.

xCures will provide access without licensing fees to the data for academic and government researchers. Open access to this valuable resource will accelerate scientific breakthroughs and foster a community actively seeking a cure.

“We recognize that collaboration is key to success. Our pledge extends to fostering an ongoing relationship with all stakeholders – patients, families, physicians, researchers, and advocacy organizations,” said Mika Newton, CEO of xCures. “Together, we can create a powerful collective dedicated to advancing the understanding and treatment of DMG DIPG.”

DMG and DIPG patients are encouraged to sign up for the study at www.xcures.com/dmg

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com

Seamless integration with existing healthcare infrastructures drives unprecedented possibilities to improve medical research and patient care.

xCures, a trailblazer in healthcare technology, is delighted to unveil xUTILITY, a solution poised to transform the patient registry paradigm in the United States.

xUTILITY establishes an instantaneous patient registry platform by retrieving records nationwide and automatically digitizing and structuring the electronic health data into a common data model with AI-enhanced abstraction and source verification, as needed.

In order to provide a 360-degree view of patient health, xUTILITY includes comprehensive capture capabilities for Electronic Health Records (EHR) and Social Determinants of Health (SDOH) data.

“The integration of research and care is the future of healthcare,” said Mika Newton, CEO of xCures. “xUTILITY brings this future to the present by delivering rich, comprehensive, and timely patient data. This connectivity will spur personalized, efficient care and groundbreaking medical discoveries.”

The platform’s ability to capture Real-Time, Regulatory-Grade Clinical Data (RRC) is pivotal to delivering quality patient care and pursuing groundbreaking medical research. 

xUTILITY’s distinctive feature is its ability to accommodate user document uploads, integrated with automated data extraction. 

The resulting synchronized data architecture introduces a new era of research-driven patient care. Its innovative data extraction process, bolstered by a complete data annotation workflow, adheres to 21 CFR Part 11, signifying xCures’ unyielding commitment to data integrity.

The unprecedented level of automation offered by xUTILITY translates to a remarkable workforce multiplier, with up to a 30-fold improvement in efficiency of data curation. This efficiency enables healthcare organizations to expedite decision-making, improve health outcomes, and enhance operational effectiveness.

With xUTILITY, xCures is charting a course toward a future where the integration of research and care forms the backbone of healthcare delivery.

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions.

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com.

xCures data deemed fit-for-purpose to address research questions relevant to the prevention, clinical care, diagnostics, and treatment in oncology.

First posted on NewsDirect

In a step forward for healthcare research, xCures is pleased to announce that it will support Aetion®’s collaboration with the US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE). As part of this partnership, xCures will provide Aetion with data to support their research collaboration agreement with OCE which centers on using real-world data (RWD) to assess real-world oncology endpoints and measure and address health disparities.

As part of the collaboration with OCE, Aetion’s comprehensive fit-for-purpose data assessment identified xCures’ real-time, regulatory-grade data platform to be an appropriate fit for this research study, particularly its ability to integrate clinical data with patient pathology, radiology reports, and imaging assessments.

“Aetion is proud to embark on this partnership with xCures to help OCE conduct pivotal research to advance the use of real-world evidence, including in measuring and understanding vulnerable and underrepresented populations,” said Liz Garry, Head of Scientific Research, Aetion. “This work furthers our mission to power critical decisions in healthcare with data science-driven technology and brings us one step closer to achieving health equity.”

xCures’ CEO, Mika Newton, explains, “Our platform’s automated organization and structuring of aggregated, continuous data result in complete, source-verifiable, and fully longitudinal clinical data sets. This rich dataset can offer unprecedented insight into the real-world patient experience.”

The contribution of robust RWD from xCures will play an integral role in this endeavor, aiming to fill knowledge gaps and facilitate advancements in healthcare research. For more information about real-time, regulatory-grade clinical data, please visit www.xcures.com/solutions.

About Aetion®
Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us on LinkedIn.

About xCures
xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, always up-to-date care summary that helps cancer patients get the right therapy at the right time.
The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions.

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials.